Growth Metrics

Sarepta Therapeutics (SRPT) Cash from Investing Activities Growth (1y) (2011 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Growth (1y) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -114.28%
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 826.39%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -674.01%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -166.24%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -122.45%
10 Sarepta Therapeutics 1.86 Bn 1.17 Bn 291.52 Mn 53.85%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 53.85%
Dec 31, 2025 -87.41%
Sep 30, 2025 280.40%
Jun 30, 2025 132.69%
Mar 31, 2025 -233.08%
Dec 31, 2024 1,287.29%
Sep 30, 2024 38.82%
Jun 30, 2024 -201.96%
Mar 31, 2024 1,651.49%
Dec 31, 2023 -756.98%
Sep 30, 2023 -1,201.37%
Jun 30, 2023 133.32%
Mar 31, 2023 101.59%
Dec 31, 2022 480.13%
Sep 30, 2022 -5.66%
Jun 30, 2022 -190.32%
Mar 31, 2022 -601.58%
Dec 31, 2021 97.92%
Sep 30, 2021 -62.52%
Jun 30, 2021 1,038.08%
Mar 31, 2021 986.12%
Dec 31, 2020 -825.36%
Sep 30, 2020 401.10%
Jun 30, 2020 -122.46%
Mar 31, 2020 -113.07%
Dec 31, 2019 107.18%
Sep 30, 2019 71.67%
Jun 30, 2019 376.58%
Mar 31, 2019 1,048.32%
Dec 31, 2018 51.85%
Sep 30, 2018 -150.74%
Jun 30, 2018 -174.72%
Mar 31, 2018 -106.79%
Dec 31, 2017 -148.37%
Sep 30, 2017 1,122.11%
Jun 30, 2017 -125.41%
Mar 31, 2017 981.17%
Dec 31, 2016 -184.70%
Sep 30, 2016 -67.04%
Jun 30, 2016 2,233.28%
Mar 31, 2016 -55.68%
Dec 31, 2015 -249.58%
Sep 30, 2015 251.01%
Jun 30, 2015 217.59%
Mar 31, 2015 124.04%
Dec 31, 2014 5,778.47%
Sep 30, 2014 -1,124.87%
Jun 30, 2014 -98.00%
Mar 31, 2014 -2,261.26%
Dec 31, 2013 -94.33%
Sep 30, 2013 -1,970.37%
Jun 30, 2013 -283.38%
Mar 31, 2013 -2,846.56%
Dec 31, 2012 46.05%
Sep 30, 2012 74.69%
Jun 30, 2012 56.18%
Mar 31, 2012 22.02%
Dec 31, 2011 -54.64%
Sep 30, 2011 34.56%